Based on the TOPAZ-1 study, do you routinely include durvalumab in first line treatment of advanced bile duct cancer?

Topics: Gastrointestinal Cancers • Medical Oncology • Liver and Pancreas Tumors

Answer from: Medical Oncologist at Academic Institution

YES! And it is a strong yes. TOPAZ-1 is a very elaborate study with statistically and clinically significant data outcomes. See Do et al., Journal of Clinical Oncology 2022. What is better than holding chemotherapy after 6 months and keeping patients on single agent durvalumab? And avoiding all...

Comments

Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty
NCCN Guidelines Version 1.2022 recommends Durvalum...

Answer from: Medical Oncologist at Community Practice

**I deleted the initial part of my answer to this question, as the TOPAZ-1 regimen has now been FDA-approved for treatment of metastatic biliary tract cancer.** It is notable also that much of the separation of survival curves in TOPAZ-1 happened after cessation of active therapy in the control...

Related Questions